Oxaprozin-Induced Apoptosis on CD40 Ligand-Treated Human Primary Monocytes Is Associated with the Modulation of Defined Intracellular Pathways
Figure 1
Oxaprozin increases apoptosis in CD40L-treated monocytes. Monocytes were incubated for 48 hours with control medium or 200 ng/mL CD40L plus 1 g/mL CD40L enhancer in the presence or absence of different doses (0, 5, 10, 50,100 M) of oxaprozin. (a) Assessment of apoptosis by acridine-orange-stained slides under fluorescence microscopy. Data are express as percentages of apoptotic cells on total number of cells counted (mean SEM, n 3; apoptosis in absence versus in presence of CD40L: *P .05; apoptosis in presence of CD40L versus CD40L plus 10 or 50 M oxaprozin: #P .05; apoptosis in presence of CD40L versus CD40L plus 100 M oxaprozin: ##P .01). (b) Assessment of apoptosis by using Annexin V and Propidium Iodide (PI) binding assay. (mean SEM, n 4; apoptosis in absence versus in presence of CD40L: *P .05; apoptosis in presence of CD40L versus CD40L plus 100 M oxaprozin: #P .05 and ##P .01).
